HEPATITIS C ELIMINATION CHALLENGES AND OPORTUNITIES CAN WE GET THERE FROM HERE?

> Iris R. Cardona, MD, FAAP Chief Medical Officer Puerto Rico Department of Health

DISCLOSURE

• I disclose that I have no financial relationship with commercial interests




Background: HCV Infection

- HCV infection causes cirrhosis and hepatocellular carcinoma and, until COVID-19, more mortality than the combined total of 60 nationally notifiable infectious conditions
- HCV infection disproportionately impacts minoritized and marginalized populations
 - Individuals with substance use disorders
 - Individuals with interactions with the Corrections system
 - Persons living in poverty




HCV Prevalence

- Worldwide 170 million (3%)
- United States 2.3 million (1.9%)
- Puerto Rico ????



Prevalencia: Puerto Rico 2.3%; San Juan 6.3%

- Genotipo por distribucion: G1 (75-80%), G2 (12.1%), G3 (3.8%) y G4 (2%)
- Prevalencia significativamente mayor en hombre (4.0%) que mujer (1.0%)
- Prevalencia de la infección in PUD: 60-85%
- 2004: aproximadamente 89,500 individuos anti-cuerpo positivo para-Hep. C




.: Kershenobich D, et al. Liver Int 2011;31 Suppl 2:18-29; 2: Perez CM, et al. BMC Infect Dis 2010;10:76; 3: Rodriguez-Perez F, et al. P R Health Sci J 2004;23:49-56; 4: Reyes JC, et al. J Urban Health 2006;83:1105-13.

CUMULATIVE DATA 2018-2022, PUERTO RICO, VITAL

8,515 diagnosed with HCV in the Vital
68% male, 32% female
7,523 mono-infected patients
992 patients co-infected with HIV and HCV

HEPATITIS C ELIMINATION

"A world where viral hepatitis transmission is halted and everyone living with hepatitis has access to safe, affordable and effective care and treatment services" WHO



Cinical Infectious Diseases



Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection


Melika Histochem, ¹⁴ Andrea Annache,² Annahis Price,⁴ and Hisson La Re H⁴, the Annexis Annalistics for the Study of Low Hommon-Advections Hannam Earlieft of Annexis NEV Endows Feed⁴

Teachers C. Marca, Jonan J. Holland, Tapano, Landon K. Mart of Marca et al., Second et al., S

The Indexistent Diseases backety of America and the American Association for the Yoshy of Liver Diseases have collaboratively developed evidence based guidance regarding the diagnosis, mategoreses, and technical of hepdatic C visco (DCV) solution source 2010. A second of chickages and Diseaseshier with empower molecular diversity or hearting areas to a so-

- Although endemic in many countries, it is possible to eliminate HCV within entire populations.
- The WHO's initiative to eliminate HCV was proposed in 2016
- Specific HCV elimination targets:
 - 90% reduction in incidence and prevalence,
 - Treatment of 80% of eligible persons with chronic infection,
 - 65% reduction in HCV-related deaths,
 - Universal access to key prevention and treatment services.
 - Focuses on promoting equity, engaging communities, and integrating hepatitis services into existing health systems.
- Needs:
 - The scientific means and tools to detect and treat.
 - Political will, popular support, and leadership for the implementation of those tools.
 - Health system capable of diagnosing, treating, and conducting followups with the entirety of the population.
 - Affordable diagnostics and drugs .
 - The final element program is its meticulous execution.

ELIMINATION OF HCV REQUIRES EFFORT ON SEVERAL FRONTS



1. WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Accessed November 17, 2020.

2. Kattakuzhy. Ann Intern Med. 2017;167:311. 3. Lazarus. Semin Liver Dis. 2018;38:181.

Slide credit: clinicaloptions.com

WHO HCV 2030 Elimination Goal? HOW CAN WE GET THERE

- One-time, routine, opt-out testing recommended for all adults
- Build community capacity to deliver quality community-based hepatitis services, supported by legal and regulatory frameworks.
- Identify good models of integrated and linked service delivery
- Define populations and locations that are most affected and require intensified support and prioritize them in the national hepatitis response


Expand testing and treatment with DAAs for those already infected

Simple testing,
diagnosis and
treatmentNon specialist
providers
(PCP)Decentralized
care in the
communitySimple
management
protocols

SIMPLIFIED CARE DELIVERY

ELIMINATION INITIATIVES BARRIERS, PUERTO RICO

- Limited screening resources
- Lack of data collection system
- The high cost of treatment
- Lack of a coordinated effort
- No elimination plan





Taha G, Ezra L, Abu -Freha N. Hepatitis C Elimination: Opportunities and Challenges in 2023. Viruses. 2023 Jun 22;15(7):1413.

HEPATITIS C ELIMINATION PLAN

1 Prevenir nuevas infecciones de hepatitis virales	2 Mejorar los resultados en la salud de las personas con un diagnóstico positivo a las hepatitis virales	3 Reducir Jas disparidades en la salud y desigualdades relacionadas con las hepatitis virales	4 Mejorar la vigilancia y el uso de datos de las hepatitis virales	5 Lograr estuerzos integrados y coordinados entre todos los socios y grupos de interés que aborden la epidemia de hepatitis virales
Aumentar los servicios de prevención y tratamiento de las hepatitis virales para las personas con uso problemático de sustancias Aumentar la capacidad de salud pública, los sistemas de cuidado de salud y el personal de salud para prevenir y tratar las hepatitis virales	 Mejorar la calidad de la atención y aumentar el número de personas con hepatitis virales que reciben y continúan (Hepatitis B) o completan (Hepatitis C) el tratamiento, incluyendo personas que utilizan drogas y personas en centros correccionales 	 Reducir las disparidades en las nuevas infecciones por hepatitis virales, el conocimiento de su estatus y a lo largo de la cascada/continuo de cuidado Ampliar los servicios de prevención, cuidado y tratamiento de las hepatitis virales que sean culturalmente competentes y lingüísticamente apropiados 	 Mejorar la vigilancia de salud pública mediante la recopilación de datos, el reporte de casos y la investigación en los departamentos de salud a nivel nacional, estatal, tribal, local y territorial 	 Integrar programas para abordar la sindemia de hepatitis virales, VIH, ITS y trastornos por uso de sustancias Mejorar los mecanismos para medir, monitorear, evaluar, reportar y difundir el progreso hacia lograr las metas organizacionales, locales y nacionales

PLAN PARA LA ELIMINACIÓN DE LAS HEPATITIS VIRALES EN PUERTO RICO

VIRAL HEPATITIS

Outlines main objectives that aim to increase access to curative medications and expand implementation of complementary efforts such as screening, testing, and provider capacity.

These objectives are designed to tackle the main elimination barriers: the will, the organization, and the cost.

National Strategic Plan A Roadmap to Elimination for the United States | 2021-2025



HEPATITIS C EPIDEMIOLOGICAL SURVEILLANCE SYSTEM

- 2016 Hepatitis C is again included as a reportable condition to the OA Department of Health Number 358.
- 2021 Puerto Rico Department of Health (DS) established the Hepatitis C Epidemiological Surveillance System (HCV).
- The main purposes included promoting standardization and data collection, investigating and describing HCV cases in Puerto Rico (PR), publishing data reports periodically, and recommending data-driven public health actions for the elimination of Hepatitis C.
- The objective of this project is to present the first phase of the implementation of a surveillance system for Hepatitis C in Puerto Rico.
- Data is collected, reviewed, analyzed, and validated on the "National Electronic Disease Surveillance System" (NEDSS)

Cráfica 6. Curva epidémica de los casos reportados de Hepatitis C durante el periodo de la semana epidemiológica número 1 (1 de enero de 2023) a la semana epidemiológica número 52 (30 de diciembre de 2023), PR 2023 — Promedio histórico




Clasificación de Caso Condición Total Confirmado* Probable* Hepatitis C Crónica 1,174 3,105 4,279 Hepatitis C Aguda 3 1 4 Hepatitis C Perinatal 1 N/A 1 1,178 3,106 Total 4,284

Tabla 2. Resumen de casos de Hepatitis C reportados, PR 2023 (N=4,284).


*Definiciones de caso según el CDC y el CSTE.

Noto. El caso de Hepatitis C perinatal fue reportado en el año 2022 e identificado en la Vigilancia de Hepatitis C del DSPR en el año 2023.



HCV Epidemiological Surveillance System,2023 Puerto Rico






Elimination Journey

Establish coverage for hepatitis C treatment of the PR-VITAL Government Health Plan

CUMULATIVE DATA 2018-2022, PUERTO RICO, VITAL

8,515 diagnosed with HCV in the Vital 68% male, 32% female 7,523 mono-infected patients

992 patients co-infected with HIV and HCV



Work on chronic Hepatitis C coverage for all patients of the Puerto Rico Government Health Plan - VITAL. A multidisciplinary work team of clinical professionals and medical specialists was organized, with continuous assessment at the highest administrative levels of ASES.

Hepatitis C: State of Medicaid Access Report Card

Remove prior authorization for HCV treatment.

Remove additional restrictions described below.

agency, which has a cooperative agreement with the Administrución de Seguros Solud de Puerto Rico (ASES),² called El Plan de Salud

Prior authorization is required for preferred HCV treatment regimens.³

VITAL (VITAL Health Plan),3 ASES implements and administers the island-wide health insurance system and contracts with four managed care organizations (MCOs)*: First Medical Health Plan, MMM Multi Health, Plan de Salud Menonita, and Triple-S Salud.¹

Recommendations to Improve Patient Access

Policy

to Ricc Puerto Rico

Grade

В


Deductions

Prior



Medicaid Access **Report Card** B

- Hepatitis C: State of Medicaid Access is the ٠ culmination of work by the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI) and the National Viral Hepatitis Roundtable (NVHR) to definitively assess the state of access to DAAs for Medicaid enrollees across America
- Through a national report and state-by-state • report cards, the project provides an in-depth evaluation of DAA access in each state's Medicaid program, while highlighting successes in access expansion as well as ongoing challenges.



batiti

State Overview

As of August 2021, 1,500.0 agency, which has a cooper VITAL (VITAL Health Plan) managed care organization

Mayvret is the preferred re

Playyret is the pres	erren re	Authorization	1.1	This automation is required for preserves new descining register	1977 A.T.		
Destruction		Fibrosis Restrictions		Puerto Rico Medicaid does not impose fibrosis restrictions.*			
Deduction Prior Authorization Fibrosis Restrictions	-8	Substance Use Restrictions	Puerto Rico Medicaid does not appear to impose substance use restrictions. However, the clinic oriteria document does note that for patients with a history of substance use, it is "recommende that the oriteria be consended and commended to for the measurement of his fort				
Substance Use Restrictions		Prescriber Restrictions		Puerto Rico Medicaid does not impose prescriber restrictions for most patients. ¹¹ Prescription by a specialist is still required for patients with certain specific "complications such as advanced liver disease, compensated cirrhosis, hepatitis B concomitant, severe renal impairment/end stage renal disease or HIV. ¹¹			
Prescriber -8		Retreatment Restrictions		Paerto Rico Medicaid does not appear to impose retreatment restrictions. ¹²			
	· · · · · · ·	Access in Managed Care		First Medical Health Plan, MMM Multi Health, Plan de Salud Menonita, and Triple-S Salud appear t impose the same requirements as FFS. ¹³			
Retreatment Restrictions		Additional Restrictions -4		Puerto Rico Medicaid imposes additional restrictions as follows: ¹⁴ Restricts coverage for people with "severe disease states or medical conditions which significantly impede compliance with treatment." For patients with compensated cirrhesis, prescriptions must be written by a specialist.			
Access in Managed Care							
		Total Deductions -12		Total Score [100-Deductions] 88	Grade B		
a ditional • trictions	-8	 "No a 	ired adl ddition	terence tracking during treatment. al supply of the medication will be authorized when th en. or missing."	e patient claims that it		
-24 To		tal Score [100-Deductions] 76	Grade				

Mavyret is the preferred regimen for Puerto Rico's Medicaid program.⁶

ASES HCV Protocol Update May 2023

PR Medicaid Special Conditions Registry Normative Letter 21-0511

- Once the patient is diagnosed with Hepatitis C, the economic cost of pharmacological treatment falls entirely on ASES (carve out).
- The patient is included in the Special Cover; this coverage for the treatment of Hepatitis C will be in effect until the patient's sustained virologic cure is certified.
- Restrictions identified as limitations on access to treatment (liver damage, sobriety, and prescribing physicians) were eliminated.
 - All PCPs can treat HCV without a special certification
 - Complicated patients can be treated by PCP in consultation
 - with a specialist
 - Aditional supply of the medication will be supplied if lost, stolen or missing
- Screening is recommended for everyone >18 years of age per the latest CDC guidelines.

FA Description	Glecaprevir and Pibrentasvir (Mavyret [®])
PA Decorption Required Medical Information	Glecaprevir and Protentasivir (Mavyret*) (I) PC/384, posted algona downered by a quantitative titer (I) PC/384, posted algona downered by a quantitative titer (I) PC/384, posted algona downered by a quantitative titer (I) PC/384, posted algona downered by a quantitative titer (I) PC/384, posted algona downered by a quantitative titer (I) PC/384, periods transmer, regions and downer, experienced. (I) provide periods transmer regions and downer, experienced. (I) provide periods transmer, regions and downer, experienced. (I) provide periods transmer regions and downer, experienced. (I) provide periods transmer, regions and downer, experienced. (I) provide periods transmer, regions and downer, estimation and beause (Stage 5) (Information will be used to very downer, experienced. (I) Role of particular threation rate (pC/Fi) OR (I) Coolinet glome-wild threation rate (pC/Fi) OR (I) Coolinet (pc/Fi) OR
	 (a) Provide Model of End Liver Doesse (MELD)^a score AND (b) Provide Oxid Pugh score (OPT)
Age Restriction	a) 3 years or more
Prescriber Restriction	a) Infectivity b) Heputingut c) Heputingut c) Galarovernendugit c) Galarovernendugit d) Liver Transplant Specialist e) Hot Specialist f) HOt Specialist f) HOt Specialist f f f) Hot Specialist f f f f f f f f f f f f f f f f f f f
Coverage	a) FA requests will be approved, for the time prescribed, however dispensing of Mavyret
Duration	must be monthly.

Revised

ST3 ASEC

ATTACHMENT 7

MANDATED AND UNIFORM PROTOCOL FOR CONDITIONS INCLUDED IN SPECIAL COVERAGE

PR Medicaid Special Conditions Registry Normative Letter 21-0511



EL CAPITOLIO SAN JUAN, PUERTO RICO 00901

Yo, Yamil Rivera Vélez, Secretario del Senado de Puerto Rico,

CERTIFICO:

Que el P. del S. 681, titulado:

"LEY

Para crear la "Ley para el Cernimiento y Diagnóstico de la Hepatitis A, B, y C en Puerto Rico", a los fines de establecer como política pública del Estado Libre Asociado de Puerto Rico la erradicación del virus de la hepatitis en sus diferentes modalidades para el 2030; proveer para que se ofrezca la prueba de cernimiento de hepatitis A, B, y C como parte de las pruebas de rutina de toda evaluación médica; proveer para que se cubran las pruebas de cernimiento y diagnóstico de la hepatitis A, B, y C, y emmendar el Artículo 3 de la Ley 232-2000, conocida como "Ley de Certificación de Salud de Puerto Rico", a los fines de incluir las pruebas de hepatitis A, B, y C entre las pruebas requeridas para obtener un certificado de salud; y para otros fines relacionades."

ha sido aprobado por el Senado de Paerto Rico y la Cámara de Representantes en la forma que expresa el ejemplar que se acompaña.

> PARA QUE ASI CONSTE, y para notificar al Gobernador de Puerto Rico, expido la presente en mi oficina en el Capitolio, San Juan, Paerto Rico, el día treinta y uno (31) del mes de mayo del año dos mil veintirrés y estampo en ella el sello del Senado de Puerto Rico.

LEY 67.20 23

Secretario del Senado

ACT 67 OF 2023 PR HEP C SCREENING AND DIAGNOSTIC LAW

- Make HCV elimination a public policy priority in Puerto Rico
- Order the inclusion of HCV testing in all rutinary medical testing
- Order the reimbursement by payors of HCV diagnostic tests
- Include HCV test as part of the tests required to obtain a Health Certificate to work.

Normative Letter 23-0728

- ASES Normative letter 23-0728 is a summary of all new changes adopted to continue making advances in HCV eradication in PR.
- It includes all previous and new important changes made to the PA protocol
- Law #67 which establishes HCV eradication as a public policy

COBIERNO DE PUERTO RICO

Carta Normativa 23-0728

28 de julio de 2023

A: Aseguradoras, Compañías de Servicios de Salud Mental, Administrador del Beneficio de Farmacia, Farmacias, Grupos Médicos Primarios y Proveedores Participantes del Plan Vital

Asunto: Actualizaciones en la cubierta de tratamiento de la Hepatitis C bajo el Plan Vital

La ASES continúa actualizando la cubierta para el tratamiento de la Hepatitis C bajo Plan Vital, conforme a la politica pública establecida por el gobierno de Puerto Rico bajo la ley 67 de 2023, donde "se establece como política pública del Estado Libre Asociado de Puerto Rico la erradicación de las Hepatitis en sus diferentes modalidades para el 2030. A partir de la aprobación de esta ley, todas las agencias del gobierno del Estado Libre Asociado de ruerto Rico deberán brindar apoyo necesario para hacer valer los propósitos de esta ley, así como cualquier otra ley o iniciativa que directa, o indirectamente contribuya al cernimiento y cuidado de salud efectivo contra la hepatita. B y C."

Es nuestro interés continuar ampliando el acceso al tratamiento de Hepatitis C de nuestra población asegurada. Se han realizado varios cambios para cumplir con lo antes mencionado, enfocados en mejorar la conexión al cuidado del paciente:

- El medicamento Mavyret fue incluido en el formulario de ASES efectivo el 26 de marzo de 2020.
- El tratamiento de Hepatitis C es cubierto por ASES por lo que ni la aseguradora ni el medico primario está a riesgo de este.
- Se eliminó el requisito de certificación para que los médicos primarios pudieran tratar la hepatitis C. De esta forma, los médicos primarios pueden recetar tratamiento de Hepatitis C sin restricción adicional.
- A tono con las guías establecidas, paciente complicado (definido en el protocolo clínico de tratamiento para la Hepatitis C de ASES) debe ser tratado en coordinación con un especialista.
- Se permite a los médicos de las redes de cada aseguradora, o fuera de ellas, emitir receta médica de Mavyret[®] u otros medicamentos para tratamiento de la Hepatitis C que deberá ser evaluada (Pre-Autorizada) por la aseguradora del paciente. Tratamiento diferente a

PO. Box 195667, San Juan, P.R. 00979-56

Mavyret debe ser evaluado mediante el proceso de excepción por la aseguradora por lo que el paciente siempre tendrá disponible tratamiento conforme a su condición medica.

- Entre otros cambios al protocolo clínico de Mavyret para facilitar el acceso al tratamiento:

 Se modificó el requisito de monitorear la adherencia al tratamiento, y se incluyó
 promover la adherencia.
 - Se removió el enunciado: "No se autorizará ningún suministro adicional del medicamento cuando el paciente afirme que se perdió, fue robado o extraviado".
 Se eliminó el requisto de realizar el *fibroscon* previo a iniciar tratamiento, pero
 - sigue siendo una de las pruebas disponibles en la cubierta especial para determinar daño hepático.
 - El fibroscan es una prueba no invasiva que mide la rigidez de su higado. Se utiliza para evaluar el grado de daño hepático en personas con hepatitis C crónica. No se requiere para el tratamiento de la hepatitis C crónica, pero puede ayudar a determinar la extensión del daño hepático y guiar las decisiones de tratamiento.
 - Paciente diagnosticado tiene derecho a ser registrado por su médico o especialista en la cubierta especial de Hepatitis C para su proceso de tratamiento. Las aseguradoras deberán seguir los criterios para registros esbozados en el anejo 7 del contrato entre ASES y las aseguradoras. No podrán exceder las 72 horas para registrar al paciente una vez la aseguradora tenga la información requerida.
 - Les recordamos que todo paciente de 18 años o más bajo Plan Vital tiene derecho a realizarse la prueba de detección al menos una (1) vez en la vida.

Exhortamos a los proveedores primarios a ordenar la prueba de detección de Hepatitis C a sus pacientes que le visiten -28 de Julio - día oficial de hacerse la prueba, en su chequeo anual o en su próxima visita.

Para observar el protocolo clínico completo pueden visitar el siguiente enlace: https://drive.google.com/drive/folders/1aMde_HO_piOwd2VtBg4k1LPn-I_leawx

Estos cambios permiten que la población actual identificada con Hepatitis C pueda tener fácil acceso al tratamiento de elección. Juntos podemos erradicar la Hepatitis C en Puerto Rico.

Cordialmente,

Edna Y. Marin Ramos, MA

Directora Ejecutiva

P.D. Box 195667, San Juan, P.R. 00993-5667

• July 28, 2023

VITAL- MARCH 2020 TO NOV 2023 1,526 PATIENTS TREATED

Service date: 3/1/2020 - 11/30/2023

1,526 pacientes tratados desde el 2020					
Dispensable_Name	HIV_Flag	Claim_Count	Utilizing_Members	Plan_Paid	Patient_Paid
Mavyret Oral Tablet 100-40 MG	Monoinfectados	3049	1553	\$40,134,380.50	\$1,428.00
Mavyret Oral Tablet 100-40 MG	Coinfectados	4	3	\$52,274.00	\$8.00
Epclusa Oral Tablet 400-100 MG	Monoinfectados	31	11	\$764,830.30	\$42.00
Sofosbuvir-Velpatasvir Oral Tablet 400-100 MG	Monoinfectados	268	89	\$2,141,761.30	\$369.00
Vosevi Oral Tablet 400-100-100 MG	Monoinfectados	19	7	\$484,116.09	\$22.00
Total pagado				\$43,577,362.19	

Dispensable_Name	Member_Gender	HIV_Flag	Claim_Count	Utilizing_Members
Mavyret Oral Tablet 100-40 MG	Female	Monoinfectados	760	389
Mavyret Oral Tablet 100-40 MG	Female	Coinfectados	2	1
Mavyret Oral Tablet 100-40 MG	Male	Monoinfectados	2289	1164
Mavyret Oral Tablet 100-40 MG	Male	Coinfectados	2	2
Epclusa Oral Tablet 400-100 MG	Female	Monoinfectados	15	5
Epclusa Oral Tablet 400-100 MG	Male	Monoinfectados	16	6
Sofosbuvir-Velpatasvir Oral Tablet 400-100 MG	Female	Monoinfectados	56	23
Sofosbuvir-Velpatasvir Oral Tablet 400-100 MG	Male	Monoinfectados	212	66
Vosevi Oral Tablet 400-100-100 MG	Female	Monoinfectados	3	1
Vosevi Oral Tablet 400-100-100 MG	Male	Monoinfectados	16	6 ADMP SECU



MICRO-ELIMINATION STRATEGIES FOR THE HARDEST TO TREAT

Hepatitis C Virus Priority Sites

Screening, management and treatment recommendations for unique and key populations.



SURVEILLANCE

Hepatitis C Virus Surveillance Strategies

Expand infrastructure & workforce

Automate reporting & review

Conduct sampling & census studies

ASSMCA PROJECT PWID Population

- Supporting patient education efforts on HCV disease awareness and burden of disease
- Enabling screening and testing through partnerships with third party providers
- Enabling the connection between ASSMCA and ASES to ensure a robust HCV provider network to connect patients swiftly to care
- Engagement with key stakeholders in the ASSMCA provider network to ensure appropriate engagement levels at all levels of the organization and share continuous learnings










ASSMCA PROJECT



JUSTICE POPULATIONS AND HCV TESTING AND TREATMENT

- Justice Populations: Incarcerated persons, pre-trial detention, probation, and parole
- Most persons with untreated HCV Infection are associated with the correctional medical system
- There has been limited HCV testing and treatment among incarcerated persons which will be required to achieve HCV elimination goals



"To deliver healthcare services to incarcerated people, <u>CH employs a hybrid management</u> model comprising of in-house direct care providers and contracted healthcare delivery through third party healthcare providers (e.g., Physicians, Mental health professionals). While most states in the U.S. have a direct-care model or use staff for administration and outsource healthcare, <u>CH's model is relatively complex and unique</u>, with the contracted vendor directly managing CH's roster staff. In FY2018, CH spent \$8,499 per incarcerated person to provide healthcare services, while median spend across U.S. mainland states was \$5,763.293." – FOMB, Certified Fiscal Plan (2021)

Simplified testing, diagnosis and treatment Non-specialist providers to manage HCV Decentralized care in the community Simple management guidelines and protocols

Programa de Salud Correccional

PROTOCOL FOR ACCESS TO HEPATITIS C TREATMENT FOR MEMBERS OF THE CORRECTIONAL POPULATION TRANSITIONING TO THE FREE COMMUNITY

- Members of the correctional population with a probable release date of six (6) months will be included in the protocol for liaison to HCV treatment
- Members of the Correctional population with HCV antibody reactive testing will require an HCV RNA test to confirm Hepatitis C infection
- VITAL, Medicaid Special Conditions Registry
- Facilitate the link to viral hepatitis C treatment of at least 95% of members of the correctional population transitioning to the free community with a positive diagnosis of viral hepatitis C in collaboration with the Puerto Rico Department of Corrections and Rehabilitation (DCR) by December 2024.
- Develop a protocol for the implementation of the Hepatitis C Test-to-Treat Model for the 9 Centers for the Prevention and Treatment of Communicable Diseases of the PR Department of Health on or before December 2024.
- Promote the use of the Hepatitis C Test-to-Treat Model protocol to be implemented in at least 20 Primary Health Centers (PHCs) in all health regions of Puerto Rico by December 2024.



Actividades	Población Objeto	Responsables	Indicador		
Objetivo 2.3	Asegurar el enlace a tratamiento del 100% de los miembros de la población correccional en transición a la libre comunidad con un diagnóstico positivo a hepatitis viral C que reciben y completan el tratamiento al 2030.				
Objetivo específico 2.3.1	Facilitar el enlace a tratamiento de hepatitis viral C de al menos el 95% de los miembros de la población correccional en transición a la libre comunidad con un diagnóstico positivo a hepatitis viral c en colaboración con el Departamento de Corrección y Rehabilitación de Puerto Rico (DCR) a diciembre de 2024.				
2.3.1.1 Establecer acuerdos colaborativos con el DCR para asegurar el enlace a tratamiento.	Participantes con un diagnóstico	Lider DSPR Administración DCR	 Acuerdo colaborativo con el DCR establecido 		
2.3.1.2 Revisión del protocolo actual de Enlace a Tratamiento de Hepatitis C de los miembros de la Población Correccional en Transición a la Libre Comunidad de <u>Physician Correctional</u> para robustecer y atemperar el protocolo.	comunidad	Lider DSPR Coordinador DSPR	Protocolo revisado		
2.3.1.2 Hacer taller educativo donde se explique el protocolo de enlace a tratamiento al personal del DCR. Personal de Departam de Corrección y Rehabilitación (coordinadores de sali		Lider DSPR Coordinador DSPR Administración DCR	 Taller educativo desarrollado # de profesionales de la salud impactados 		

CONNECTING PATIENT TO CARE IS POSSIBLE

Test and Treat Model for PCPs, FQCHC


persons living with HIV:


- FIB-4 >3.25

- Liver biopsy

imaging

Current pregnancy





HEPATITIS C IN HIV COINFECTED PATIENTS

- Ryan White Program/ADAP, treating eligible patients
- 54 Clinical Centers
- From 2015 to 2022, 453 treated patients
- 98% treated patients reached SVR (Cure)

SUMMARY



- The elimination of chronic HCV is urgent and important.
- Many factors interact to determine the success of an elimination program
- Initial Challenges:
 - National policy plan
 - Availability of epidemiological data
 - Awareness of HCV among the general population and high-risk groups
- The simplification of treatment access, and treatments tailored to the different settings are key aspects towards achieving HCV elimination.
- Prioritize at-risk populations, such as PWIDs and prisoners
- Despite the challenges entailed, effort to eliminate hepatitis C is essential to reduce morbidity and mortality.

